BMC Med Res Methodol 2016;16:148. (95% CI 2.01, 6.30), < 0.0001] thrombosis. Anti-2-glycoprotein I IgA positivity was also a significant risk factor for any [2.00 (1.22, 3.3), = 0.0065] thrombosis. Table 2 Relationship between venous thrombosis and the most recent past assessment of each aPL < 0.0001] thrombosis. Anti-2-glycoprotein I IgA positivity was also a significant risk factor for venous [2.8 (1.42, 5.51), = 0.0029] thrombosis. Table 3 Relationship between arterial thrombosis and the most recent past assessment of each aPL = 0.005] thrombosis. Since the aPL are correlated, we examined whether an association between each specific aPL and thrombosis was seen after adjustment for the presence of LA. We found that the association between anti-2-glycoprotein I IgA any [1.73 (1.04, 2.88), (?)3.9 (2.14, 7.09)<0.00015.8 (2.56, 13.15)<0.00013.11 (1.34, 7.23)0.0084?aCL-G (+) (?)0.63 (0.22, 1.81)0.39100.47 (0.1, 2.13)0.32891.04 (0.3, 3.62)0.9449Model 2: LA + aCL-M?LA (+) (?)3.88 (2.16, 6.98)<0.00015.09 (2.28, 11.36)<0.00013.41 (1.5, 7.78)0.0035?aCL-M (+) (?)0.53 (0.16, 1.73)0.29380.76 (0.17, 3.31)0.71570.61 (0.14, 2.63)0.5083Model 3: LA + aCL-A?LA (+) (?)3.42 (1.9, 6.13)<0.00014.67 (2.11, 10.34)0.00013.06 (1.36, 6.88)0.007?aCL-A (+) (?)1.86 (0.44, 7.89)0.39812.14 (0.28, 16.56)0.46591.57 (0.21, 11.97)0.6623Model 4: LA + aB2GPI-G?LA (+) (?)3.68 (2.01, 6.71)<0.00014.85 (2.09, 11.28)0.00023.23 (1.41, 7.44)0.0058?aB2GPI-G (+) (?)0.84 (0.29, KB-R7943 mesylate 2.41)0.74081.03 (0.29, 3.73)0.96170.84 (0.19, 3.69)0.8172Model 5: LA + aB2GPI-M?LA (+) (?)3.71 (2.08, 6.64)<0.00014.99 (2.26, 11.02)<0.00013.32 (1.47, 7.47)0.0038?aB2GPI-M (+) (?)0.76 (0.38, 1.52)0.43410.88 (0.34, 2.3)0.80080.72 (0.28, 1.83)0.4875Model 6: LA + aB2GPI-A?LA (+) (?)3.16 (1.76, 5.68)0.00013.95 (1.77, 8.83)0.00082.96 (1.31, 6.68)0.0091?aB2GPI-A (+) (?)1.73 (1.04, 2.88)0.03622.27 (1.13, 4.59)0.02181.33 (0.64, 2.78)0.4469 Open in a separate window aCL-G: aCL IgG; aCL-M: aCL IgM; aCL-A: aCL IgA; aB2GPI-G: anti-2-glycoprotein I IgG; aB2GPI-M: anti-2-glycoprotein KB-R7943 mesylate I IgM; aB2GPI-A: anti-2-glycoprotein I IgA; age-adj. RR: age-adjusted rate ratio. Next, we fitted a model to look at the relationships between combinations of LA and other aPL and the risk of any, venous and arterial thrombosis. We created four categories based on combinations of LA and other aPL: both negative; both positive; LA positive, aPL (i) negative; LA negative, aPL (i) positive; where aPL (i) could be aCL IgG/M/A or anti-2-glycoprotein I IgG/M/A. In this interaction model, LA remained the best predictor of thrombosis. The risk of any thrombosis after adding anti-2-glycoprotein I IgA to LA was 2.3 times the risk for those who had LA without anti-2-glycoprotein I IgA. However, it did not reach statistical significance (P?=?0.1253). Adding other aPL with different isotypes did not seem to increase the risk of any thrombosis (Table?5). Table 5 Relationship between aPL with LA and risk of ANY thrombosis

(1) LA and aCL-GLA (+), aCL-G (?)1123247.41.00 (ref)LA (+), aCL-G (+)38634.70.76 (0.21, 2.74)0.6715LA (-), aCL-G (+)11815.50.12 (0.02, 0.93)0.042LA (-), aCL-G (?)73575412.70.27 (0.14, 0.51)<0.0001(2) LA and aCL-MLA (+), aCL-M (?)1225447.21.00 (ref)LA (+), aCL-M (+)26431.20.63 (0.14, 2.85)0.5537LA (?), aCL-M (+)11905.30.11 (0.01, 0.84)0.0334LA (?), aCL-M (?)73574612.70.26 KB-R7943 mesylate (0.14, 0.49)<0.0001(3) LA and aCL-ALA (+), aCL-A (?)1330342.91.00 (ref)LA (+), aCL-A (+)11664.11.42 (0.18, 11)0.7352LA (?), aCL-A (+)12933.90.74 (0.1, 5.74)0.7739LA (?), aCL-A (?)73590612.40.29 (0.16, 0.52)<0.0001(4) LA and aB2GPI-GLA (+), aB2GPI-G (?)1124644.71.00 (ref)LA (+), aB2GPI-G (+)37241.40.96 (0.27, 3.46)0.9481LA (?), aB2GPI-G (+)11267.90.18 (0.02, 1.39)0.1000LA (?), aB2GPI-G (?)73581012.60.28 (0.15, 0.53)<0.0001(5) LA and aB2GPI-MLA (+), aB2GPI-M (?)1123447.11.00 (ref)LA (+), aB2GPI-M (+)38535.40.73 (0.2, 2.64)0.6333LA (?), aB2GPI-M (+)66129.80.2 (0.08, 0.56)0.0018LA (?), aB2GPI-M (?)68532412.80.27 (0.14, 0.51)<0.0001(6) LA and aB2GPI-ALA (+), aB2GPI-A (?)722031.81.00 (ref)LA (+), aB2GPI-A (+)79871.42.28 (0.8, 6.52)0.1253LA (?), aB2GPI-A (+)1370918.30.58 (0.23, 1.45)0.2438LA (?), aB2GPI-A (?)61522711.70.37 (0.17, 0.8)0.0119 KB-R7943 mesylate Open in a separate window aCL-G: aCL IgG; aCL-M: aCL IgM; aCL-A: aCL IgA; aB2GPI-G: anti-2-glycoprotein I IgG; aB2GPI-M: anti-2-glycoprotein I IgM; aB2GPI-A: anti-2-glycoprotein I IgA; age-adj. RR: age-adjusted rate ratio. Incident cases of thrombosis were reduced when we looked at venous and arterial thrombosis separately. In combinations with aCL, we did not find any cases with venous thrombosis. Adding other aPL (anti-2-glycoprotein I IgG/IgM) with different isotypes did not increase the risk of venous thrombosis. Anti-2-glycoprotein I IgA numerically increased the TSPAN2 risk of venous thrombosis among those with LA, but statistically it was not significant (P?=?0.1081). In arterial thrombosis, we did not find any additive risk of anti-2-glycoprotein I IgA to LA. In.